Eylea(aflibercept)
Eylea, Zaltrap (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Eylea, Zaltrap
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diabetic retinopathy | EFO_0003770 | D003930 | — |
| macular edema | — | D008269 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX44: Aflibercept
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA05: Aflibercept
Clinical
Clinical Trials
422 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 14 | 27 | 31 | 23 | 33 | 123 |
| Macular edema | D008269 | 9 | 18 | 27 | 25 | 18 | 91 | ||
| Colorectal neoplasms | D015179 | 5 | 21 | 6 | 1 | 3 | 33 | ||
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 4 | 5 | 10 | 8 | 8 | 32 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 3 | 6 | 5 | 6 | 19 | |
| Diabetic retinopathy | D003930 | EFO_0003770 | 1 | 7 | 1 | 5 | 3 | 16 | |
| Retinal neovascularization | D015861 | H35.05 | — | 4 | — | 2 | 1 | 7 | |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | 1 | 2 | 1 | 2 | 6 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 1 | 1 | — | 4 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | 2 | 1 | 4 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 13 | 2 | 1 | — | — | 15 | |
| Choroidal neovascularization | D020256 | 1 | 2 | 2 | — | 4 | 9 | ||
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | 3 | — | 1 | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | 1 | 3 | — | — | 5 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 3 | 1 | — | — | 5 |
| Neovascular glaucoma | D015355 | EFO_1001060 | — | — | 2 | — | 3 | 5 | |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | — | 3 | — | 1 | 4 |
| Retinal degeneration | D012162 | HP_0001105 | — | 1 | 2 | — | — | 3 | |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | 1 | — | — | 3 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | 1 | — | — | 3 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | 6 | — | — | 1 | 7 | ||
| Colonic neoplasms | D003110 | C18 | — | 3 | — | — | 2 | 5 | |
| Melanoma | D008545 | 1 | 2 | — | — | — | 3 | ||
| Corneal neovascularization | D016510 | EFO_1000880 | H16.4 | 2 | 1 | — | — | — | 2 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | 1 | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 2 |
| Esophageal neoplasms | D004938 | C15 | 1 | 1 | — | — | — | 2 | |
| Fallopian tube neoplasms | D005185 | 1 | 2 | — | — | — | 2 | ||
| Ovarian epithelial carcinoma | D000077216 | 1 | 2 | — | — | — | 2 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 2 | — | — | — | — | 2 | |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Glioma | D005910 | EFO_0000520 | 1 | — | — | — | — | 1 | |
| Retinal arterial macroaneurysm | D000080346 | 1 | — | — | — | — | 1 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Choroid diseases | D015862 | HP_0000610 | H31.9 | — | — | — | — | 1 | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | — | 1 | 1 |
| Intravitreal injections | D058449 | — | — | — | — | 1 | 1 | ||
| Intraocular pressure | D007429 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AFLIBERCEPT |
| INN | aflibercept |
| Description | Aflibercept (immunoadhesin) |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 862111-32-8 |
| RxCUI | 1232150 |
| ChEMBL ID | CHEMBL1742982 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08885 |
| UNII ID | 15C2VL427D (ChemIDplus, GSRS) |
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zaltrap - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Eylea - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,529 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,710 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more